

## DAFTAR PUSTAKA

- Agusweni, T., Yulia, I. D., Erwin., 2020. Gambaran Faktor Resiko Insiden Karsinoma Ovarium di RSUD Arifin Achmad Provinsi Riau. *Jurnal Ners Indonesia* . Vol. 11(1): 35-50.
- Akinwunmi, B.O., Babic, A., Vitonis, A.F., 2018. Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer. *Cancer Epidemiology Biomarkers Prev.* 27(12):1483-1490.
- Aktürk, E., Karaca, R.E., Alanbay, I., 2011. Comparison of four malignancy risk indices in the detection of malignant ovarian masses. *Journal Gyneco Oncology.* 22(3):177-82.
- Amante, S., Santos, F & Cunha, T.M., 2021. Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists. *Insights Imaging.* 12(60), pp. 1-12.
- Amante, S., Santos, F. and Cunha, T.M., 2021. Low-grade serous epithelial ovarian cancer: a comprehensive review and update for radiologists. *Insights into Imaging,* 12(1), pp.1-12.
- Anastasi, E., T. Granato., R. Falzarano., P. Storelli. *Et al.* 2013. The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. 6(44).
- Andrijono. 2009. *Sinopsis Karsinoma Ginekologi.* Fakultas Kedokteran Universitas Indonesia, RS Dr Cipto Mangunkusumo. (hal. 59-126).
- Arania, R & Windarti, I., 2015. Karakteristik pasien karsinoma ovarium di Rumah Sakit Dr. H. Abdul Moeloek Bandar Lampung. *Jurnal kedokteran Universitas Lampung.* Vol5(9):43-7.
- Ariani, S., 2015. *Stop Karsinoma.* Yogyakarta : Istana Media
- Ariningtyas, N.D., 2018. CA 125 dan Pemakaian Klinis dalam Penatalaksanaan Karsinoma Ovarium. *Qanun Medika,* 2(2), 73 – 82
- Azis, M. F, Andrijono, Saifuddin AB. 2006. *Acuan Nasional Onkologi Ginekologi.* Yayasan Binas Pustaka Sarwono Prawirohardjo FKUI. 1st Ed. Jakarta, hal. 468-527.
- Babaier, A & Ghatage, P., 2020. Mucinous Cancer of the Ovary: Overview and Current Status. *Diagnostics,* 10(52), pp. 1 – 16.
- Bae, H.S., Kim, H.J., Hong, J.H., Lee, J.K., Lee, *Et al.* 2014. Obesity and epithelial ovarian cancer : a systematic review and meta-analysis. *Journal of ovarian research.* 7(41), pp. 1-8.
- Banerjee, S & Kaye, S.B., 2013. New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential. *Clinical Cancer Research* 19(5), pp. 961 – 968.

- Barakat, R.R., Berchuc, A., Markman, M & Randall, M.E., 2015. *Principles and practice of gynecologic oncology. 6th ed.* Philadelphia (PA) : Wolters Kluwer.
- Berek, J.S, English, D.P., Longacre, T.A & Friedlander M., 2020. *Ovarian, Fallopian Tube, and Peritoneal Cancer.* In: Berek, J.S., eds. *Berek and Novak's Gynecology.* 16 ed. Philadelphia: Lippincott Williams & Wilkins. pp. 2541-69.
- Berek, J.S., 2002. Ovarian Cancer. *Novak's Gynecology.* H. Moore. Philadelphia, Lippincott : Williams & Wilkins.
- Blackburn, L.M., Abel, S., Green, L., Jhonson, K., & Panda, S., 2019. The Use of Comfort Kits to Optimize Adult Cancer Pain Management. *Pain Management Nursing.* Vol 20(1), pp. 25-31.
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.E., Torre, L.*Et al.* 2018. Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence And Mortality Worldwide for 36 Cancers in 185 Countries. *Cancer Journal for Clinicians.* 68(6), pp. 394–424.
- Budiana, I.N.G., Michelle, A & Pemayun, T.G.A., 2019. Ovarian cancer: Pathogenesis and current. *J Turk Ger Gynecol Assoc.* 20(1), pp. 47-54.
- Canadian Cancer Society. 2017. *Canadian cancer statistics.* Toronto: Canadian Cancer.
- Chang., L.C., Huang, C.F., Lai, M.S., Shen, L.J., Wu, F.L.L & Cheng, W.F., 2018. Prognostic factors in epithelial ovarian cancer: A population-based study. *PLoS ONE.* 13(3), pp. 1-11.
- Colombo, P.E., Fabbro, M., Theillet, C., Bibeau, F., Rouanet, P,*Et al.* 2013. Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. *Journal Critical reviews in oncology/hematology.*89(2), pp. 207-216.
- Dahlan, S., 2013. *Statistik untuk Kedokteran dan Kesehatan Edisi 5.* Jakarta: Salemba Medika
- Erickson, B.K., Conner, M.G & Landen, C.N.J., 2013. The role of fallopian tube in the origin of ovarian cancer. *Am Journal Obstetry Gynecology.* 209(5), pp. 409–14.
- Eroschenko, V. P., 2016. *Atlas Histologi DiFiore.* Jakarta: EGC
- Fathalla, M.F.. 2013. Incessant ovulation and ovarian cancer a hypothesis revisited. *FVV in OBGYN.* 5(4), pp. 292-297.
- Global Cancer Statistics 2018 : GLOBOCAN Estimates of Incidence And Mortality Worldwide for 36 Cancers in 185 Countries. *Cancer Journal for Clinicians.* 68(6), pp. 394–424.
- Globocan, 2018. The Global Cancer Observatory. GLOBOCAN
- Globocan. 2020. International Agency for Research on Cancer. The Global Cancer Observatory.
- Gong, T.T., Wu, Q.J., Vogtmann, E., Lin, B & Wang, Y.L., 2014. Age at menarche and

- risk of ovarian cancer. *International Journal Cancer*. 132(12), pp. 2894-900.
- Gross, A.L., Kurman, R.J., Vang, R., Shih, I.M & Visvanathan, K., 2010. Precursor lesion of high grade serous ovarian carcinoma: morphological and molecular characteristics. *Journal Oncology*. 2010, pp. 1-9.
- Høgdall, E.V., Christensen, L., Kjaer, S.K., Blaakaer, J., Thygesen, K., Gayther, S., Jacobs, I.*Et al.* 2007. CA 125 expression pattern, prognosis and correlation with serum CA 125 in ovarian carcinoma patients. *Gynecology Oncology*. 104(3), pp. 508-15.
- Johari, B.A., 2013. Insidensi karsinoma ovarium berdasarkan faktor risiko di RSUP Haji Adam Malik tahun 2008-2011. *E-Jurnal FK USU*. 1(1):1-6.
- Karst, A.M & Drapkin, R., 2010. Ovarian Cancer Pathogenesis: A Model in Evolution. *Journal of Oncology*. 2010, pp. 1 – 13.
- King, T. G. G., Leighton, J. C., Staros, E. B. 2021. CA-125: Laboratory Medicine. Medscape.
- Koshiyama, M., Matsumura, N & Konishi, I., 2014. Recent concepts of ovarian carcinogenesis: Type I and Type II. *Biomed Res Int*. 2014, pp. 1-11.
- Kumar, V., Abbas, A.K & Aster, J.C., 2015. *Robbins Basic Pathology. 9th ed.* Philadelphia. Elsevier.
- Kurman RJ, Shih IM. The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory. *Am J Surg Pathol*. 2010;34:433–43. [PMC free article] [PubMed] [Google Scholar]
- Lalwani, N. Prasad, S.R. Vikram, R., Shanbhogue, A.K., Huettner, P.*Et al.* 2011. Histologic, Molecular, and Cytogenetic Features of Ovarian Cancers: Implications for Diagnosis and Treatment. *RadioGraphics*. 31(1),pp. 625-646.
- Lisnawati., 2013. Gambaran Faktor-faktor risiko Penderita Karsinoma Ovarium di RSUD Labuang Baji Makassar [KTI]. Makassar: Fakultas Ilmu Kesehatan UIN Alaudin Makassar (Tidak Dipublikasikan).
- Matulonis, U.A., Sood, A.K., Fallowfield, L., Howitt, B.E., Sehouli, J & Karlan, B.Y., 2016. Ovarian Cancer. *Nature Reviews Disease Primers*. 2(16061), 1– 22.
- Mescher, A. L., 2017. *Histologi Dasar Junqueira edisi 12*. Jakarta: Penerbit Buku Kedokteran EGC.
- Momenimovahed, Z., Tiznobaik, A., Taheri, S & Salehiniya, H., 2019. Ovarian Cancer in The World Epidemiology And Risk Factors. *International Journal of Women's Health*. 11(1), pp. 287–299.
- Moore, K.L., Dalley, A.F., Agur, A.M.R & Moore M.E., 2013. *Anatomi berorientasi klinis. Edisi ke-5*. Jakarta: Erlangga.
- Nakagawa, N., Koda, H., Nitta, N., Nakahara, Y., Uno, J & Hashimoto, T., 2015.

- Reactivity of CA19-9 and CA 125 in histological subtypes of epithelial ovarian carcinoma and ovarian endometriosis. *Acta Med. Okayama*. 69(4), pp. 227-35.
- Netter, Frank H. 2016. *Atlas Anatomi Manusia Bahasa Latin/ Indonesia Edisi 6*. Indonesia: Elsevier.
- Nurlailiyani. Hubungan Antara Usia Pasien Dengan Derajat Keganasan Carcinoma Ovarium Primer Di RSUD Dr. Moewardi Tahun 2011-2012 . 2013. *Skripsi*. Solo: Universitas Negeri Sebelas Maret (Tidak Dipublikasikan).
- Panjaitan, H. 2015. Hubungan Indeks Resiko Keganasan dengan Jenis Histopatologi Tumor Epitel Ganas Ovarium di RSHAM 2011-2014. hal 3.
- Prawirohardjo S. 2013. *Ilmu kandungan. Edisi ke-3*. Jakarta: PT Bina Pustaka Sarwono
- Prayitno S. 2014. *Buku Lengkap Kesehatan Organ Reproduksi Wanita, Edisi ke-1*. Jakarta: Saufa.
- Rancourt C, Matte I, Lane D, Piche A. 2012. The role of MUC16 mucin (CA 125) in the pathogenesis of ovarian cancer. *Ovarian Cancer- Basic Science Perspective*. www.intechopen.com.
- Rasjidi. 2013. *Buku Ajar Onkologi Klinik*. Jakarta:EGC.
- Rumah Sakit Prof. Dr. Margono Soetardjo. 2020. Data Open 10 Besar Kasus Rawat Jalan Klinik Onkologi Ginekologi di RSMS RSUD Margono Soekarjo 2020. Purwokerto.
- Sastroasmoro, S & Sofyan I., 2016. *Dasar-dasar Metodologi Penelitian Klinis Edisi 5*. Jakarta: Sagung Seto.
- Schorge, J.O., Joseph, I.S., Bradshaw, K & Halvorson, L.M., *Williams gynecology. 2nded*. Mc Graw Hill; 2008.
- Schunke, M., Schulte, E., & Schumacher, U., 2017. *Atlas Anatomi Manusia Prometheus: Kepala, Leher, & Neuroanatomi*. Jakarta. EGC.
- Sherwood, L., 2014. *Human physiology from cells to systems. Edisi ke-8*. Belmont,CA: Brooks/cole.
- Siegel, R.L., Miller, K.D & Jemal, A., 2016. Cancer statistics. *CA Cancer J. Clin.* 66(7), pp. 7-30
- Silverthorn, D.U., 2014. *Fisiologi manusia sebuah pendekatan terintegrasi. Edisi ke-2*. Jakarta: EGC.
- Simamora, R.P.A., Hanriko, R & Sari, R.D.P., 2018. Hubungan Usia, Jumlah Paritas, dan Usia Menarce Terhadap Derajat Histopatologi Karsinoma Ovarium di RSUD Dr. H. Abdul Moeloek Bandar Lampung Tahun 2015- 2016. *Majority*. 7(2), pp. 7-13.
- Singh, N., McCluggage, W.G & Gilks, C.B., 2017. High-Grade Serous Carcinoma of Tubo-Ovarian Origin: Recent Developments. *Histopathology*. 71(3), pp.339-56.
- Snell, R S., 2017. *Anatomi Klinis : Berdasarkan Sistem* . Jakarta: EGC.

- Sturgeon, C. M., M. J. Duffy., U. H. Stenman., H. Lilja., N. Brümer., D. W. Chan., R. Babaiian., J. R. R. C. *Et al.* 2008. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. 54 (12).
- Tortora, G.J & Derrickson, B., 2017. *Principles of Anatomy & Physiology*. United States of America: John Wiley & Sons, Inc.
- Wijaya, R., Krisna, M., Zen, H. 2017. Hubungan Kadar CA-125 Dengan 125 Dengan Subtipe Epitel Carcinoma Ganas Ovarium Pada Penderita Yang Dirawat Di RSUP Dr. Mohammad Hoesin Palembang Tahun 2013-2016. *Majalah Kedokteran Sriwijaya*. (4), pp. 197-204.
- World Health Organization. 2014. *Cancer Country Profile: Indonesia*. Didapat dari [https://www.who.int/cancer/country-profiles/idn\\_en.pdf](https://www.who.int/cancer/country-profiles/idn_en.pdf)
- World Health Organization. 2014. *Epithel Ovarian Cancer. Union for International Cancer Control 2014* . Review of Cancer Medicines on the WHO List of Essential Medicines.
- World Health Organization. 2018. Indonesia source globocan 2018 Int. *Agency Res. Cancer*. vol. 256, pp. 1–2.
- Zayyan, S., 2020. *Risk Factors for Ovarian Cancer. Karsinoma Progression and Metastasis*. London: Intech Open.

